CN102908325A - Sevelamer carbonate medical tablet composition and preparation method thereof - Google Patents
Sevelamer carbonate medical tablet composition and preparation method thereof Download PDFInfo
- Publication number
- CN102908325A CN102908325A CN2012104489751A CN201210448975A CN102908325A CN 102908325 A CN102908325 A CN 102908325A CN 2012104489751 A CN2012104489751 A CN 2012104489751A CN 201210448975 A CN201210448975 A CN 201210448975A CN 102908325 A CN102908325 A CN 102908325A
- Authority
- CN
- China
- Prior art keywords
- propen
- chloromethyl
- tablet composition
- amine polymer
- oxirane carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a sevelamer carbonate medical tablet composition and a preparation method thereof. The tablet composition comprises the following components in parts by weight: 60-95 parts of sevelamer carbonate, 5-30 parts of crospovidone and 0.1-10.0 parts of silicon dioxide. The preparation method of the tablet composition comprises the following steps: a. sevelamer carbonate is mixed with crospovidone; b. the mixture obtained in step a is pelletized; c. silicon dioxide is mixed with the particles produced in step b to form tablets; d. the tablets obtained is film-coated by water-soluble coating materials. The tablet composition provided by the invention is characterized in that the formability is good, the rigidity is high, the disintegration is quick, and the disintegration is less affected by the rigidity.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, relate to a kind of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate medicinal tablets composition and method of making the same.
Background technology
As everyone knows, End-stage Renal Disease Patients ubiquity hyperphosphatemia, and also hyperphosphatemia can cause hyperparathyroidism and osteodystrophy.Recently research finds that hyperphosphatemia still can bring out soft tissue and angiosteosis, is the key factor that End-stage Renal Disease Patients mortality rate and cardiovascular disease increase.Therefore, effectively control the serum paraoxonase level and become the Important Action that reduces End-stage Renal Disease Patients mortality rate and cardiovascular disease incidence rate.The at present treatment of hyperphosphatemia mainly comprises application and the in case of necessity parathyroid excision of diet limit phosphorus, dialysis treatment, phosphate binder.The absorption of phosphorus at first should dietary restriction, but too strict restriction can cause malnutrition again, then particularly evident for dialysis patient.Fully dialysis treatment can be removed unnecessary phosphorus in the body, however 3 times weekly of current extensive implementation, and the hemodialysis mode of each 4h usually is not enough to remove unnecessary phosphorus in the body.There is 90%～5% End-stage Renal Disease Patients need to take phosphate binder treatment hyperphosphatemia.
2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate be by U.S. Genzyme company former grind be used for nonabsorbable ion exchange resin in conjunction with phosphoric acid, commodity are called Renvela
TM, be a kind of crosslinked polyallylamine carbonate, chemistry poly-(pi-allyl amido-be total to-N N '-diallyl-1,3-diaminourea-2-hydroxy propane) by name carbonate, its molecular structure is similar to the mesh resin structure.Structural formula is as follows:
A, b are the number a+b=9 of primary amine group
C is the number c=1 of crosslinked group
M is a polymer network that larger number expression is extended
Research is found, 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate has highly hydrophilic, can in gastrointestinal tract, hydration expand into the gel that is several times as much as original volume, a plurality of amino that it carries under the physiological pH can be in the small intestinal inner proton and positively charged, be combined with bile acid with enteral phosphate radical by ion exchange and hydrogen bond, reduce phosphate level in the blood of human body.Moreover, the sevelamer hydrochloride of comparing is because the chloride ion that contains seldom, so can avoid renal failure patient's sour toxemia tendency.2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate treatment hyperphosphatemia has the following advantages: (1) reduces End-stage Renal Disease Patients serum paraoxonase level greatly; (2) with calcic, contain the aluminum phosphate binder and compare, 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate can not cause hypercalcemia or poisoning by aluminum, thus the calitriol that can give patient's higher dosage is controlled secondary hyperparathyroidism better; (3) can avoid using the patient blood acidosis tendency to occur.
But the compressibility of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate crude drug is relatively poor, often hardness is low for the plain sheet of compacting, and friability is high, and the plain sheet disintegration time of compacting is also longer, can't satisfy the requirement of follow-up coating process, perhaps coating disintegration of tablet time limit of finishing can not be satisfied the General Requirements of tablet.
Although the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate compressibility can be improved by adding more adjuvant, this technical thought is because the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate clinical dosage is larger and restricted.2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate clinical treatment dosage is larger, the therapeutic dose of recommending is 2.4-4.8g/ days (2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate sheet description), therefore the specification of its preparation is also corresponding larger, be 800mg/ sheet or 400mg/ sheet such as its tablet specification, the amount of adding adjuvant in the tablet of so large specification will inevitably be subject to larger restriction, otherwise can cause tablet weight and volume too large and so that patient when taking tablet, encounter difficulties.
Prior art is attempted the solution of the above-mentioned technical problem in the manufacturing of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate tablet.The starting point that its problem solves focuses mostly on and limits and optimize in the pharmaceutical properties to the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate principal agent, to improve the compressibility of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate.Document CN00814607.1 points out to control in the tablet within the principal agent water content 3%-10%, even the adjuvant that adds seldom also can be with the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate compression forming.Document EP 099714841 prompting particle diameter (is crossed 32 mesh sieves) below 500 μ m ratio accounts for that sevelamer hydrochloride 90.0% or more uses separately or as required with specific additive and make tablet, and the gained tablet has that hardness height, phosphate-binding energy are excellent, disintegrate advantage rapidly.
We find by research, the solution that above-mentioned 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate compressibility is improved, and the technical scheme of control principal agent water content ranges can not realize the effect that it is declared; And the other technologies scheme too harsh to the restriction of principal agent or technique is high to the requirement of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate raw material, and condition is many, and be also inconvenient in the use, also is not easy to industrialization and promotes with producing.
Summary of the invention
The objective of the invention is the defects for prior art, a kind of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate medicinal tablets compositions is provided.
Another object of the present invention provides the preparation method of this tablet composition.
Purpose of the present invention can be achieved through the following technical solutions:
The 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate tablet composition contains the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate of 60 ~ 95 weight portions, the polyvinylpolypyrrolidone of 5 ~ 30 weight portions and the silicon dioxide of 0.1 ~ 10.0 weight portion.
Described tablet composition preferably contains the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate of 60 ~ 90 weight portions, the polyvinylpolypyrrolidone of 5 ~ 20 weight portions and the silicon dioxide of 0.1 ~ 5.0 weight portion.
Described tablet composition also comprises one or more pharmaceutically acceptable lubricants.
Preferred 0.5 ~ 5.0 weight portion of the content of described lubricant.
In the preferred magnesium stearate of described lubricant, stearic acid, Glyceryl Behenate, PEG6000, the Pulvis Talci any one or multiple.
The preparation method of tablet composition of the present invention may further comprise the steps:
A, the conventional method of use are mixed 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate with polyvinylpolypyrrolidone;
B, with a gained granulating mixture, can be dry granulation, can be wet granulation also, add the water of about 6 ~ 13 weight portions, use the conventional equipment such as dry granulating machine or oscillating granulator to granulate;
C, silicon dioxide is mixed with the made granule of b, prepare plain sheet;
D, gained element sheet use water solublity coating material film coating; Described water solublity coating material is this area coating material commonly used, can make by oneself, also can buy as required easy to be a kind of water solublity coating material of selling on the market, such as the gastric solubility coating material;
The incorporation time of silicon dioxide and granule is between 30 seconds-360 seconds, between preferred 30 seconds-180 seconds in the c step.
Wherein, 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate is 60 ~ 95 weight portions, preferred 60 ~ 90 weight portions; Polyvinylpolypyrrolidone is 5 ~ 30 weight portions, preferred 5 ~ 20 weight portions; Silicon dioxide is 0.1 ~ 10.0 weight portion, preferred 0.1 ~ 5.0 weight portion.
Beneficial effect:
The present invention passes through research and finds when the pharmaceutic adjuvant polyvinylpolypyrrolidone that adds certain weight ratio and silicon dioxide, beyond thought result has appearred in the manufacturing of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate tablet, even that is: the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate raw material is not done more specific (special) requirements, adopt conventional wet granulation technique or dry powder granulation technique just can obtain having above 140N hardness with less than the plain sheet of the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate of 1% friability, its gained element sheet can satisfy the specification requirement of follow-up coating process, and the obtained 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate disintegration of tablet time is not more than 10 minutes.
The specific embodiment
Embodiment 1,
Prepare tablet according to prescription and following technique in the table 1, tablet is measured hardness and friability, is listed in the table below:
With supplementary material, except silicon dioxide, according to above proportioning wet mixing pelletizer, add the water mix homogeneously, granulate with oscillating granulator 20 orders, again silicon dioxide is added in the granule, mix homogeneously is pressed into plain sheet, measures hardness and the friability of plain sheet.
Table 1
Research is found to use dissimilar adjuvant and 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate mixing granulation tabletting, only has when using polyvinylpolypyrrolidone to be main filler, and the hardness of plain sheet and friability can reach the basic demand of tablet.The adjuvant gained element sheet friability of other kinds all can not be less than 1% requirement.
Embodiment 2
Prepare tablet according to table 2 proportioning: with 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate and polyvinylpolypyrrolidone mixing, add the purified water mixing, granulate with oscillating granulator 20 orders, granule again with the silicon dioxide mixing, be pressed into plain sheet, measure hardness and the friability of plain sheet.
Table 2
Contrast and experiment shows: do not add silicon dioxide and polyvinylpolypyrrolidone is united use, the friability of the plain sheet of preparation and hardness all can not meet the requirements; And, each prescription of the polyvinylpolypyrrolidone of adding 50-200mg and the silicon dioxide of 1-50mg, the plain sheet of preparation all can reach the requirement of friability and hardness.
Embodiment 3
Prepare tablet according to table 3 proportioning: with 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate and polyvinylpolypyrrolidone mixing; add the purified water mixing, granulate with oscillating granulator 20 orders; granule again with the mixings such as silicon dioxide, magnesium stearate, stearic acid, Glyceryl Behenate, PEG6000, Pulvis Talci; be pressed into plain sheet, measure hardness and the friability of plain sheet.
Table 3
Experimental result shows: increase lubricant at the basis prescription and can improve the flowability of midbody particle, and do not affect the indexs such as the hardness of plain sheet and friability.
Embodiment 4,
Prepare tablet according to table 4 proportioning: with 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate and polyvinylpolypyrrolidone mixing; add the purified water mixing, granulate with dry granulating machine 20 orders; granule again with silicon dioxide, magnesium stearate, mixing; go sample to be pressed into plain sheet in different incorporation times, measure hardness and the friability of each incorporation time element sheet.
Table 4
Find that by test incorporation time has certain influence for our plain sheet hardness and friability.The hardness that incorporation time prolongs plain sheet slightly descends, and friability slightly raises.And another aspect, incorporation time is too short, and then the mixing of principal agent 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate and adjuvant can not be even, obtained tablet hardness homogeneity existing problems.Incorporation time 30-360S effect is better.
Embodiment 5:
The preparation of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate 400mg sheet, it is as shown in table 5 to write out a prescription:
Table 5
1,2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate was pulverized 45 mesh sieves.
2, will mix 5min in 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate, the polyvinylpolypyrrolidone adding mixer.
3, water is added wet-mixed 5min.
4, with granulating mixture, granule is crossed 20 orders.
5, silicon dioxide, magnesium stearate are added, mix 90S.
6, tabletting, specification 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate 400mg/ sheet, 1000 of quantity.
7, slice, thin piece is carried out hardness, friability, disintegration time mensuration, the results are shown in Table 6.
Table 6
| Prescription | Hardness (N) | Friability (%) | Disintegration (min) |
| Prescription 20 | 230 | 0.45 | 2 |
| Prescription 21 | 212 | 0.57 | 2 |
8, coating
The coating powder consumption calculates with 4% of plain sheet weight.
Get purified water 255ml, will
Gastric solubleness coating powder 20.4g stirs dissolving in 1 hour.
Plain sheet is added respectively in the coating pan spray coating.
Unilateral uniform and smooth, the clothing film is complete.
Coating weightening finish about 4%.
Embodiment 6:
The preparation of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate 800mg sheet, it is as shown in table 7 to write out a prescription:
Table 7
1,2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate was pulverized 45 mesh sieves.
2, will mix 5min in 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate, the polyvinylpolypyrrolidone adding mixer.
3, water is added wet-mixed 5min.
4, with granulating mixture, granule is crossed 20 orders.
5, silicon dioxide, magnesium stearate are added, mix 180S.
6, tabletting, specification 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate 800mg/ sheet, 1000 of quantity.
7, slice, thin piece is carried out hardness, friability, disintegration time mensuration, the results are shown in Table 8:
Table 8
| Prescription | Hardness (N) | Friability (%) | Disintegration (min) |
| Prescription 22 | 204 | 0.68 | 2 |
| Prescription 23 | 215 | 0.61 | 2 |
8, coating
The coating powder consumption calculates with 4% of plain sheet weight.
Get purified water 510ml, will
Gastric solubleness coating powder 40.8g stirs dissolving in 1 hour.
Plain sheet is added respectively in the coating pan spray coating.
Unilateral uniform and smooth, the clothing film is complete.
Coating weightening finish about 4%.
Claims (8)
1. the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate tablet composition is characterized in that containing the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate of 60 ~ 95 weight portions, the polyvinylpolypyrrolidone of 5 ~ 30 weight portions and the silicon dioxide of 0.1 ~ 10.0 weight portion.
2. tablet composition according to claim 1 is characterized in that containing the 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate of 60 ~ 90 weight portions, the polyvinylpolypyrrolidone of 5 ~ 20 weight portions and the silicon dioxide of 0.1 ~ 5.0 weight portion.
3. tablet composition according to claim 1 is characterized in that described tablet composition also comprises one or more pharmaceutically acceptable lubricants.
4. tablet composition according to claim 3, the content that it is characterized in that described lubricant is 0.5 ~ 5.0 weight portion.
5. tablet composition according to claim 4, it is characterized in that described lubricant be in magnesium stearate, stearic acid, Glyceryl Behenate, PEG6000 or the Pulvis Talci any one or multiple.
6. the preparation method of each described tablet composition in the claim 1 ~ 6 may further comprise the steps:
A, the conventional method of use are mixed 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate with polyvinylpolypyrrolidone,
B, with a gained granulating mixture,
C, silicon dioxide is mixed with the made granule of b, prepares plain sheet,
D, gained element sheet use water solublity coating material film coating;
It is characterized in that: the incorporation time of silicon dioxide and granule is 30 seconds to 360 seconds in the c step.
7. preparation method according to claim 6 is characterized in that incorporation time is between 30 seconds ~ 180 seconds in the c step.
8. preparation method according to claim 6 is characterized in that 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate content is 400mg/ sheet or 800mg/ sheet in the prepared tablet.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210448975.1A CN102908325B (en) | 2012-11-12 | 2012-11-12 | Sevelamer carbonate medical tablet composition and preparation method thereof |
| PCT/CN2013/081256 WO2014071757A1 (en) | 2012-11-12 | 2013-08-12 | Sevelamer carbonate medicinal tablet composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210448975.1A CN102908325B (en) | 2012-11-12 | 2012-11-12 | Sevelamer carbonate medical tablet composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102908325A true CN102908325A (en) | 2013-02-06 |
| CN102908325B CN102908325B (en) | 2014-07-30 |
Family
ID=47607066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210448975.1A Active CN102908325B (en) | 2012-11-12 | 2012-11-12 | Sevelamer carbonate medical tablet composition and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102908325B (en) |
| WO (1) | WO2014071757A1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071757A1 (en) * | 2012-11-12 | 2014-05-15 | 南京生命能科技开发有限公司 | Sevelamer carbonate medicinal tablet composition and preparation method thereof |
| CN104546781A (en) * | 2014-12-22 | 2015-04-29 | 青岛正大海尔制药有限公司 | Sevelamer carbonate tablet and preparation method thereof |
| CN104739786A (en) * | 2013-12-25 | 2015-07-01 | 杭州民生滨江制药有限公司 | Sevelamer carbonate tablet and preparation method thereof |
| CN104825406A (en) * | 2014-02-09 | 2015-08-12 | 江苏信孚药业有限公司 | Preparation process for sevelamer hydrochloride tablet |
| CN107157947A (en) * | 2017-05-04 | 2017-09-15 | 方达医药技术（苏州）有限公司 | A kind of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate piece and preparation method thereof |
| CN107397734A (en) * | 2017-08-24 | 2017-11-28 | 青岛正大海尔制药有限公司 | A kind of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate tablet of stabilization and preparation method thereof |
| CN108338975A (en) * | 2017-01-25 | 2018-07-31 | 北京泰德制药股份有限公司 | A kind of composition and preparation method thereof containing sevelamer or its pharmaceutical salts |
| CN108904455A (en) * | 2018-07-20 | 2018-11-30 | 汤臣倍健股份有限公司 | A kind of preparation method of the tablet containing high dose grease ingredient |
| CN109715142A (en) * | 2016-06-14 | 2019-05-03 | 苏州韬略生物科技有限公司 | 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate for tabletting |
| CN110664772A (en) * | 2019-09-27 | 2020-01-10 | 方达医药技术（苏州）有限公司 | Sevelamer carbonate tablet and preparation method thereof |
| CN111773190A (en) * | 2020-06-24 | 2020-10-16 | 北京瑞迪道森医药科技有限公司 | Sevelamer carbonate tablet for improving safety of preparation and preparation method thereof |
| CN112220762A (en) * | 2020-09-07 | 2021-01-15 | 湖北华世通生物医药科技有限公司 | Sevelamer carbonate coated tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1382041A (en) * | 1999-10-19 | 2002-11-27 | 吉尔特药品公司 | Direct comperession polymer tablet core |
| WO2011135591A2 (en) * | 2010-04-29 | 2011-11-03 | Shasun Pharmaceuticals Limited | Novel tablet composition of polyallylamine polymers |
| CN102641251A (en) * | 2012-04-19 | 2012-08-22 | 天津太平洋制药有限公司 | Underwater-dispersible tablet of Sevelamer carbonate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908325B (en) * | 2012-11-12 | 2014-07-30 | 南京生命能科技开发有限公司 | Sevelamer carbonate medical tablet composition and preparation method thereof |
-
2012
- 2012-11-12 CN CN201210448975.1A patent/CN102908325B/en active Active
-
2013
- 2013-08-12 WO PCT/CN2013/081256 patent/WO2014071757A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1382041A (en) * | 1999-10-19 | 2002-11-27 | 吉尔特药品公司 | Direct comperession polymer tablet core |
| WO2011135591A2 (en) * | 2010-04-29 | 2011-11-03 | Shasun Pharmaceuticals Limited | Novel tablet composition of polyallylamine polymers |
| CN102641251A (en) * | 2012-04-19 | 2012-08-22 | 天津太平洋制药有限公司 | Underwater-dispersible tablet of Sevelamer carbonate |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071757A1 (en) * | 2012-11-12 | 2014-05-15 | 南京生命能科技开发有限公司 | Sevelamer carbonate medicinal tablet composition and preparation method thereof |
| CN104739786A (en) * | 2013-12-25 | 2015-07-01 | 杭州民生滨江制药有限公司 | Sevelamer carbonate tablet and preparation method thereof |
| CN104739786B (en) * | 2013-12-25 | 2017-08-15 | 杭州民生滨江制药有限公司 | 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate tablet and preparation method |
| CN104825406B (en) * | 2014-02-09 | 2018-04-13 | 江苏信孚药业有限公司 | A kind of sevelamer hydrochloride tablet producing technology |
| CN104825406A (en) * | 2014-02-09 | 2015-08-12 | 江苏信孚药业有限公司 | Preparation process for sevelamer hydrochloride tablet |
| CN104546781A (en) * | 2014-12-22 | 2015-04-29 | 青岛正大海尔制药有限公司 | Sevelamer carbonate tablet and preparation method thereof |
| CN109715142A (en) * | 2016-06-14 | 2019-05-03 | 苏州韬略生物科技有限公司 | 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate for tabletting |
| CN108338975A (en) * | 2017-01-25 | 2018-07-31 | 北京泰德制药股份有限公司 | A kind of composition and preparation method thereof containing sevelamer or its pharmaceutical salts |
| CN107157947A (en) * | 2017-05-04 | 2017-09-15 | 方达医药技术（苏州）有限公司 | A kind of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate piece and preparation method thereof |
| CN107397734A (en) * | 2017-08-24 | 2017-11-28 | 青岛正大海尔制药有限公司 | A kind of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate tablet of stabilization and preparation method thereof |
| CN107397734B (en) * | 2017-08-24 | 2020-06-30 | 正大制药（青岛）有限公司 | Stable sevelamer carbonate tablet and preparation method thereof |
| CN108904455A (en) * | 2018-07-20 | 2018-11-30 | 汤臣倍健股份有限公司 | A kind of preparation method of the tablet containing high dose grease ingredient |
| CN108904455B (en) * | 2018-07-20 | 2021-04-02 | 汤臣倍健股份有限公司 | A method for preparing tablet containing high-dose oil ester component |
| CN110664772A (en) * | 2019-09-27 | 2020-01-10 | 方达医药技术（苏州）有限公司 | Sevelamer carbonate tablet and preparation method thereof |
| CN111773190A (en) * | 2020-06-24 | 2020-10-16 | 北京瑞迪道森医药科技有限公司 | Sevelamer carbonate tablet for improving safety of preparation and preparation method thereof |
| CN112220762A (en) * | 2020-09-07 | 2021-01-15 | 湖北华世通生物医药科技有限公司 | Sevelamer carbonate coated tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102908325B (en) | 2014-07-30 |
| WO2014071757A1 (en) | 2014-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102908325B (en) | Sevelamer carbonate medical tablet composition and preparation method thereof | |
| CN104546781A (en) | Sevelamer carbonate tablet and preparation method thereof | |
| TW446562B (en) | Pharmaceutical composition for increasing calcium uptake | |
| CN102895204B (en) | Sevelamer carbonate crude drug for preparing tablets, preparation method and application thereof | |
| CN104771377A (en) | Preparation method of immediate release oral preparation containing sitagliptin or sitagliptin pharmaceutical salt | |
| CN110664772A (en) | Sevelamer carbonate tablet and preparation method thereof | |
| CN103191432B (en) | Water-soluble medicine framework sustained release tablet and preparation method thereof | |
| KR101659746B1 (en) | Colonic purgative compositions comprising sulfate salts and a method for preparing the same | |
| CN112220762B (en) | Sevelamer carbonate coated tablet and preparation method thereof | |
| CN113244179B (en) | Lanthanum carbonate tablet with good stability, preparation method and application thereof | |
| CN104739786B (en) | 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate tablet and preparation method | |
| CN107397734B (en) | Stable sevelamer carbonate tablet and preparation method thereof | |
| WO2013177833A1 (en) | Dysmenorrhea-treating medicament and preparation method therefor | |
| CN102836135A (en) | Aspirin enteric-coated tablet and preparation process thereof | |
| CN103393610B (en) | Preparation for quickly disintegrating fatty amine polymer salt | |
| CN104434840A (en) | Repaglinide tablet and preparation method thereof | |
| CN101780090B (en) | Tablet containing valsartan and hydrochlorothiazide | |
| CN104825406B (en) | A kind of sevelamer hydrochloride tablet producing technology | |
| CN113018314B (en) | Pharmaceutical composition and kit for treating phosphorus metabolic disorder | |
| CN103271886A (en) | Pirfenidone tablet and preparation method thereof | |
| CN108338975A (en) | A kind of composition and preparation method thereof containing sevelamer or its pharmaceutical salts | |
| Gao et al. | Preparation of allylamine-grafted cellulose by Ce (IV): a desirable candidate of oral phosphate binders | |
| Ramarao et al. | Design of tinidazole Matrix tablets of for colon specific drug delivery employing Eudragit S 100, PEG 6000 and lactose | |
| CN111450068A (en) | Sevelamer carbonate pharmaceutical composition and preparation method thereof | |
| CN107375218A (en) | A kind of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate oral sustained-release dry suspension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANJING HENCER PHARMACY CO., LTD. Effective date: 20141114 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20141114 Address after: 210016 Huangpu building, Huangpu Road, Jiangsu, 5F, Patentee after: Nanjing Lifenergy R&D Co., Ltd. Patentee after: NANJING HENCER PHARMACY CO., LTD. Address before: 210016 Huangpu building, Huangpu Road, Jiangsu, 5F, Patentee before: Nanjing Lifenergy R&D Co., Ltd. |